We are advised by Alphamab Oncology that journalists and other readers should disregard the news release, A Phase I/II Clinical Study of Anti-HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 was Included in the Pilot Program for Optimizing the Review and Approval of Clinical Trials for Innovative Drugs, issued 13-Nov-2024 over PR Newswire.
source: Alphamab Oncology
【你點睇?】長和將全球43個港口出售,你是否擔心事件引發漣漪效應,影響本港企業在全球的業務?► 立即投票